• Home
  • Effect of some probiotics on Salmonella paratyphi during associated growth in milk

Share To

Article Url


Manuscript ID : 518222 Visit : 313 Page: 875 - 882

Article Type: Original Research

Effect of some probiotics on Salmonella paratyphi during associated growth in milk

Subject Areas : Veterinary Clinical Pathology

حمید Mirzaei 1 , افشین Javadi 2 , یوسف Angouri 3

1 - Associate Professor Department of Food Hygiene, Faculty of Veterinary Medicine, Islamic Azad University- Tabriz Branch, Tabriz,
2 - Associate Professor Department of Food Hygiene, Faculty of Veterinary Medicine, Islamic Azad University- Tabriz Branch, Tabriz,
3 - Graduate of Veterinary Medicine, Faculty of Veterinary Medicine, Islamic Azad University- Tabriz Branch, Tabriz, Iran

Received: 2008-10-28 Accepted : 2011-02-15 Published : 2010-11-22

Keywords: Milk, probiotics, Salmonella paratyphi, associated growth,

Abstract :

      The aim of this study is to determine the effects of Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium angulatom and Bifidobacterium bifidum on salmonella paratyphi in associated condition in milk. At first a quantity of 1.5 × 108 cfu/ml activated S. paratyphi was added to 500 ml of sterile milk and after homogenization distributed equally in five erlene meyers. The first erlene meyer was considered as individual culture and in to the second, third, fourth and fifth erlene meyer a quantity of 1.5×108 cfu/ml of the above probiotic was inoculated respectively and after 24-48 hours of incubation at 37 oC, pH was measured by pH meter and S. paratyphi count was determined by pour plate method in SSA medium. This procedure was repeated 10 times and the mean of pH and number of S. paratyphi in one ml of individual culture and with probiotic cultures was compared using statistical analysis.  According to statistical tests of ANOVA and Tukey at α=0.05, in 24 and 48 hour incubation of associated growth of L. acidophilus, L. casei and B. bifidum had significant inhibitory effect on S. paratyphi growth (p<0.01). However, in similar condition associated growth of L. angulatum did not show significant inhibitory effect on S. paratyphi growth. Meanwhile, in 24 and 48 hour incubation of associated growth of L. acidophilus, L. casei and B. bifidum reduced the mean of pH of milk samples compared to control sample significantly (p<0.01). These results show the consumption of probiotic products containing B. angulatom, B. bifidum, L. acidophilus and L. casei could have beneficial effects in prevention of Salmonella paratyphi infection. Although further research especially at in vivo condition in this aspect should be carried out.

References:


  1. Alakomi, H.L., Skytta, E., Saarela, M., Mattila-Sandholm, T., Latva-Kala, K. and Helander, I.M. 2000. Lactic acid permeabilizes Gram-negative bacteria by disrupting the outer membrane, Appl. Environ. Microbiol. 66:2001-2005.
    2.
  2. Bartlett, J.G., Chang, T.W. and Gurwith, M. 1987. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N. Engl. J. Med. 57:141-145.
    3.
  3. Blaut, M.D., Collins, M., Welling, G.W., Dore, J., van Loo, J. and de Vos, W. 2002. Molecular biological methods for studying the gut microbiota: The EU human gut flora project. British Journal of Nutrition. 87:203-211.
    4.
  4. Borgia, M., Sepe, N., Brancato, V. and Borgia, R.A. 1982. A controlled clinical study on Streptococcus faecium preparation for the prevention of side reactions during long-term antibiotic therapy. Curr. Ther. Res. 31:265-271.
    5.
  5. Colombel, J.F., Corot, A., Neut, C. and Romond, C. 1987. Yoghurt with Bifidobacterium longum reduces erythromycin-induced gastrointestinal effects. Lancet. 2:43.
    6.
  6. Dieuleveux, V., Lemarinier, S. and Gueguen, M. 1998.  Antimicrobial spectrum and target site of D-3-phenyllactic acid. Int. J. Food Microbiol. 40:177-183.
    7.
  7. Duncan, S., Louis, P. and Flint, H.J. 2004.  Lactate-utilizing bacteria, isolated from human faeces that reduce butyrate as a major fermentation product. Appl. Environ. Microbiol. 70:5810-5817.
    8.
  8. Fooks, L.J. and Gibson, G.R. 2002. In vitro investigations of the effect of probiotics and prebiotics on selected human intestinal pathogens, FEMS Microbiol. Ecol. 39:67-75.
    9.
  9. Fujiwara, S., Hashiba, H., Hirota, T. and Forstner, J.F. 1997. Proteinaceous factor(s) in culture supernatant fluids of Bifidobacteria which prevents the binding of enterotoxigenic Escherichia coli to gangliotetraosylceramide. Applied and Environmental Microbiology. 63:506-512.
    10.
  10. Fujiwara, S., Hashiba, H., Hirota, T. and Forstner, J.F. 1999. Purification and characterization of a novel protein produced by Bifidobacterium longum SBT2928 that inhibits the binding of enterotoxigenic Escherichia coli Pb176 (CFA/II) to angliotetraosylceramide. Journal of Applied Microbiology. 86:615-621.
    11.
  11. Fujiwara, S., Hashiba, H., Hirota, T. and Forstner, J.F. 2001. Inhibition of the binding of enterotoxigenic Escherichia coli Pb176 to human intestinal epithelial cell line HCT-8 by an extracellular protein fraction containing BIF of Bifidobacterium longum SBT2928: Suggestive evidence of blocking of the binding receptor gangliotetraosylceramide on the cell surface. International Journal of Food Microbiology. 67:97-106.
    12.
  12. Fuller, R. 1989. Probiotics in man and animals. Journal of Applied Bacteriology. 66:365-378.
    13.
  13. Gagnon, M., Kheadr, E.E., Le Blay, G. and Fliss, I. 2004. In vitro inhibition of Escherichia coli O157:H7 by bifidobacterial strains of human origin. International Journal of Food Microbiology. 92:69-78.
    14.
  14. Gibson, G.R. and Wang, X. 1994. Regulatory effects of bifidobacteria on the growth of other colonic bacteria. Journal of Applied Bacteriology. 77:412-420.
    15.
  15. Gomes, A.M.P. and Malcata, F.X. 1999. Bifidobacterium spp. and Lactobacillus acidophilus: Biological, biochemical, technological and therapeutical properties relevant for use as probiotics. Trends in Food Science and Technology. 10:139-157.
    16.
  16. Gorbach, S.L., Chang, T.W. and Goldin, B. 1987. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG. Lancet. 26:1519.
    17.
  17. Guarner, F. and Malagelada, J.R. 2003. Gut flora in health and disease. Lancet. 361:512-519.
    18.
  18. Hill, G.B., Eschenbach, D.A. and Holmes, K.K. 1984. Bacteriology of the vagina. Scandinavian Journal of Urology and Nephrology. 86:23-S39.
    19.
  19. Holzapfel, W.H., Haberer, P., Snel, J., Schillinger, U. and Huis in’t Veld, J.H. 1998. Overview of gut flora and probiotics. International Journal of Food Microbiology. 41:85-101.
    20.
  20. Ibrahim, S. and Bezkorovainy, A. 1993. Inhibition of Escherichia coli by bifidobacteria. Journal of Food Protection. 56:713-715.
    21.
  21. Lavermicocca, P., Valerio, F. and Visconti, A. 2003. Antifungal activity of phenyllactic acid against molds isolated from bakery products. Appl. Environ. Microbiol. A 69:634-640.
    22.
  22. Macfarlane, S. and Macfarlane, G.T. 2003.  Regulation of short-chain fatty acid production, Proc. Nutr. Soc. 62:67-72.
    23.
  23. Marteau, P., Seksik, P. and Jian, R. 2002. Probiotics and intestinal health effects: A clinical perspective. British Journal of Nutrition, 88(Suppl 1):51-S57.
    24.
  24. Niku-Paavola, M.L., Laitila, A., Mattila-Sandholm, T. and Haikara. M. 1999. A new type of antimicrobial compounds produced by Lactobacillus plantarum. J. Appl. Microbiol. 86:29-35.
    25.
  25. Ogawa, M., Shimizu, K., Nomoto, K., Tanaka, R., Hamabata, T., Yamasaki, S., Takeda, T. and Takeda, Y. 2001. Inhibition of in vitro growth of Shiga toxin producing Escherichia coli O157:H7 by probiotic Lactobacillus strains due to production of lactic acid. Int. J. Food Microbiol. 68:135-140.
    26.
  26. Reid, G., Jass, J., Sebulsky, M.T. and McCormick, J.K. 2003. Potential uses of probiotics in clinical practice. Clinical Microbiology Reviews. 16:658-672.
    27.
  27. Salminen, S., Isolauri, E. and Salminen, E. 1996. Clinical uses of probiotics for stabilizing the gut mucosal barrier: Successful strains and future challenges. Antonie Van Leeuwenhoek. 70:347-358.
    28.
  28. Salminen, S., Ouwehand, A.C. and Isolauri, E. 1988. Clinical application of probiotic bacteria. Int. Dairy J. 8:563-572.
    29.
  29. Servin, A.L. 2004. Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiology Reviews. 28:405-440.
    30.
  30. Siitonen, S., Vapaatalo, H., Salminen, S., Gordin, A., Saxelin, M., Wikberg, R. and Kirkkola, A. 1990. Effect of Lactobacillus GG. yoghurt in prevention of antibiotic associated diarrhoea. Ann. Med. 22:57-59.
    31.
  31. Topping, D.L. and Clifton, P.M. 2001.  Short-chain fatty acids and human colonic function: Roles of resistant starch and nonstarch polysaccharides., Physiol. Rev. 81:1031-1064.
    32.
  32. Valerio, F., Lavermicocca, P., Pascale, M. and Visconti. A. 2004.  Production of phenyllactic acid by lactic acid bacteria. An approach to the selection of strains contributing to food quality and preservation. FEMS Microbiol. Lett. 233:289-295.
    33.
  33. Vaughan, E.E. and Mollet, B. 1999. Probiotics in the new millennium. Nahrung. 43:148-S153. 
    34.

Related articles

The rights to this website are owned by the Raimag Press Management System.
Copyright © 2021-2024

Home| Login| About Us| Contact Us|
[فارسی] [العربية] [fa] [ar]